{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:25:54Z","timestamp":1790814354101,"version":"4.1.0"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02050-5","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:36:49Z","timestamp":1771389409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies"],"prefix":"10.1007","volume":"26","author":[{"given":"Xin","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuchong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh Rahmani","family":"Seraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2248-6239","authenticated-orcid":false,"given":"Dilbar","family":"Urazbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3555-4489","authenticated-orcid":false,"given":"Zamira","family":"Atamuratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4567-0576","authenticated-orcid":false,"given":"Abdullaeva Dilbar","family":"Ubaydullaevna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"3","key":"2050_CR1","first-page":"89","volume":"30","author":"J Tate","year":"2009","unstructured":"Tate J, Mollee P, Johnson R. Monoclonal gammopathies\u2013clinical and laboratory issues. Clin Biochem Rev. 2009;30(3):89\u201391.","journal-title":"Clin Biochem Rev"},{"key":"2050_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215247","author":"R R\u00edos-Tamayo","year":"2022","unstructured":"R\u00edos-Tamayo R, et al. Monoclonal gammopathies of clinical significance: a critical appraisal. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14215247.","journal-title":"Cancers (Basel)"},{"key":"2050_CR3","doi-asserted-by":"publisher","first-page":"117822421986823","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235.","journal-title":"Palliat Care Soc Pract"},{"issue":"5","key":"2050_CR4","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.clml.2023.02.004","volume":"23","author":"J Kaur","year":"2023","unstructured":"Kaur J, et al. Monoclonal gammopathy of undetermined significance: A comprehensive review. Clin Lymphoma Myeloma Leuk. 2023;23(5):e195\u2013212.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2050_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","volume":"185","author":"Y Liu","year":"2025","unstructured":"Liu Y, Parks AL. Diagnosis and management of monoclonal gammopathy of undetermined significance: a review. JAMA Intern Med. 2025;185(4):450\u20136.","journal-title":"JAMA Intern Med"},{"key":"2050_CR6","doi-asserted-by":"crossref","unstructured":"Padala SA et al. Epidemiology, Staging, and management of multiple myeloma. Med Sci (Basel). 2021;9(1):3.","DOI":"10.3390\/medsci9010003"},{"issue":"1","key":"2050_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12672-024-00938-w","volume":"15","author":"M Zhou","year":"2024","unstructured":"Zhou M, et al. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. Discover Oncol. 2024;15(1):78.","journal-title":"Discover Oncol"},{"issue":"1","key":"2050_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14(1):194.","journal-title":"Blood Cancer J"},{"key":"2050_CR9","doi-asserted-by":"crossref","unstructured":"Iannozzi NT, Giuliani N, Storti P. Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance. Front Immunol, 2025. Volume 16\u20132025.","DOI":"10.3389\/fimmu.2025.1613265"},{"issue":"1","key":"2050_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14(1):158.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2050_CR11","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.044","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa U, et al. Is it possible to predict tumor progression through genomic characterization of monoclonal gammopathy and smoldering multiple myeloma? Mediterr J Hematol Infect Dis. 2024;16(1):e2024044.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"7","key":"2050_CR12","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1097\/HS9.0000000000000744","volume":"6","author":"MC Bennink","year":"2022","unstructured":"Bennink MC, et al. Impact of comorbidities on health-related quality of life in nontransplant eligible patients with newly diagnosed multiple myeloma. Hemasphere. 2022;6(7):e744.","journal-title":"Hemasphere"},{"issue":"12","key":"2050_CR13","doi-asserted-by":"publisher","first-page":"Itc177","DOI":"10.7326\/AITC202212200","volume":"175","author":"WI Gonsalves","year":"2022","unstructured":"Gonsalves WI, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Ann Intern Med. 2022;175(12):Itc177\u201392.","journal-title":"Ann Intern Med"},{"issue":"22","key":"2050_CR14","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412\u20137.","journal-title":"Blood"},{"issue":"8","key":"2050_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"2050_CR16","first-page":"e70281","volume":"8","author":"K Ito","year":"2025","unstructured":"Ito K, et al. Progression of IgM monoclonal gammopathy of renal significance (MGRS) to symptomatic Waldenstr\u00f6m macroglobulinemia: A case report. Cancer Rep (Hoboken). 2025;8(7):e70281.","journal-title":"Cancer Rep (Hoboken)"},{"key":"2050_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061554","author":"OC Lomas","year":"2020","unstructured":"Lomas OC, et al. Monoclonal gammopathy of undetermined significance (MGUS)-not so asymptomatic after all. Cancers (Basel) 2020;3.\u00a0https:\/\/doi.org\/10.3390\/cancers12061554.","journal-title":"Cancers (Basel)"},{"issue":"9727","key":"2050_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","volume":"375","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri A, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375(9727):1721\u20138.","journal-title":"Lancet"},{"issue":"11","key":"2050_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229\u201353.","journal-title":"Blood"},{"issue":"4","key":"2050_CR20","first-page":"331","volume":"4","author":"KP Verma","year":"2023","unstructured":"Verma KP, Steuer R, Edwards CV. Geographic prevalence patterns and modifiable risk factors for monoclonal gammopathy of undetermined significance. Hematol. 2023;4(4):331\u201349.","journal-title":"Hematol"},{"issue":"13","key":"2050_CR21","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"2050_CR22","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","volume":"82","author":"O Landgren","year":"2007","unstructured":"Landgren O, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82(12):1468\u201373.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2050_CR23","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","volume":"82","author":"M Iwanaga","year":"2007","unstructured":"Iwanaga M, et al. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007;82(12):1474\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2050_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, et al. Long-Term Follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"2050_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jdv.13847","volume":"31","author":"D Lipsker","year":"2017","unstructured":"Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol. 2017;31(1):45\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"2050_CR26","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"20","key":"2050_CR27","first-page":"3069","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos M-V. Smoldering Multiple Myeloma Blood. 2015;125(20):3069\u201375.","journal-title":"Smoldering Multiple Myeloma Blood"},{"issue":"10","key":"2050_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.","journal-title":"Blood Cancer J"},{"key":"2050_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","author":"A Garc\u00eda-Ortiz","year":"2021","unstructured":"Garc\u00eda-Ortiz A, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers (Basel). 2021;217.\u00a0https:\/\/doi.org\/10.3390\/cancers13020217.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2050_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/10428194.2023.2216818","volume":"64","author":"N Kreiniz","year":"2023","unstructured":"Kreiniz N, Gertz MA. Understanding high-risk smoldering multiple myeloma. Leuk Lymphoma. 2023;64(8):1361\u201372.","journal-title":"Leuk Lymphoma"},{"issue":"16suppl","key":"2050_CR31","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1200\/JCO.2024.42.16_suppl.7556","volume":"42","author":"M Ji","year":"2024","unstructured":"Ji M, et al. From criteria to clinic: how updated slim CRAB criteria influence multiple myeloma diagnostic activity. J Clin Oncol. 2024;42(16suppl):7556\u20137556.","journal-title":"J Clin Oncol"},{"issue":"25","key":"2050_CR32","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582\u201390.","journal-title":"N Engl J Med"},{"issue":"8","key":"2050_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1182\/blood.2021011670","volume":"140","author":"I Vaxman","year":"2022","unstructured":"Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828\u201338.","journal-title":"Blood"},{"issue":"6","key":"2050_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2050_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, et al. Multiple myeloma. Nat Reviews Disease Primers. 2024;10(1):45.","journal-title":"Nat Reviews Disease Primers"},{"issue":"5","key":"2050_CR36","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s41375-022-01529-w","volume":"36","author":"A Visram","year":"2022","unstructured":"Visram A, et al. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio\u2009\u2265\u2009100. Leukemia. 2022;36(5):1429\u201331.","journal-title":"Leukemia"},{"issue":"1","key":"2050_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, et al. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5(1):25.","journal-title":"Mol Biomed"},{"issue":"5","key":"2050_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jama.2021.25306","volume":"327","author":"J Silberstein","year":"2022","unstructured":"Silberstein J, Tuchman S, Grant SJ. What is multiple myeloma? JAMA. 2022;327(5):497\u2013497.","journal-title":"JAMA"},{"issue":"1","key":"2050_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2141.2008.07547.x","volume":"145","author":"B Nair","year":"2009","unstructured":"Nair B, et al. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. Br J Haematol. 2009;145(1):134\u20137.","journal-title":"Br J Haematol"},{"issue":"10","key":"2050_CR40","first-page":"e19131","volume":"13","author":"C Silva","year":"2021","unstructured":"Silva C, et al. Light-chain multiple myeloma: a diagnostic challenge. Cureus. 2021;13(10):e19131.","journal-title":"Cureus"},{"issue":"7","key":"2050_CR41","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.22.02114","volume":"41","author":"Donk","year":"2023","unstructured":"Donk. N.W.C.J.v.d., How we manage newly diagnosed multiple myeloma with Circulating tumor cells. J Clin Oncol. 2023;41(7):1342\u20139.","journal-title":"J Clin Oncol"},{"issue":"25","key":"2050_CR42","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","volume":"126","author":"M-L Chretien","year":"2015","unstructured":"Chretien M-L, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015;126(25):2713\u20139.","journal-title":"Blood"},{"issue":"2","key":"2050_CR43","doi-asserted-by":"publisher","first-page":"103920","DOI":"10.1016\/j.sjbs.2023.103920","volume":"31","author":"MS Abduh","year":"2024","unstructured":"Abduh MS. An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities. Saudi J Biol Sci. 2024;31(2):103920.","journal-title":"Saudi J Biol Sci"},{"issue":"2","key":"2050_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41408-020-0285-6","volume":"10","author":"G Baril\u00e0","year":"2020","unstructured":"Baril\u00e0 G, et al. Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer J. 2020;10(2):18.","journal-title":"Blood Cancer J"},{"issue":"3","key":"2050_CR45","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","volume":"102","author":"T Cyrille","year":"2017","unstructured":"Cyrille T, et al. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica. 2017;102(3):e112\u20134.","journal-title":"Haematologica"},{"issue":"1","key":"2050_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, et al. Natural history of t(11;14) multiple myeloma. Leukemia. 2018;32(1):131\u20138.","journal-title":"Leukemia"},{"issue":"11","key":"2050_CR47","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"J.J Castillo","year":"2020","unstructured":"Castillo J.J., et al. Consensus treatment recommendations from the tenth international workshop for Waldenstr\u00f6m macroglobulinaemia. Lancet Haematol. 2020;7(11):e827\u201337.","journal-title":"Lancet Haematol"},{"key":"2050_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081837","author":"A Trojani","year":"2021","unstructured":"Trojani A, et al. Identification of a candidate gene set signature for the risk of progression in IgM MGUS to smoldering\/symptomatic Waldenstr\u00f6m macroglobulinemia (WM) by a comparative transcriptome analysis of B cells and plasma cells. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13081837.","journal-title":"Cancers (Basel)"},{"key":"2050_CR49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.18632\/oncotarget.28415","volume":"14","author":"M Bou Zerdan","year":"2023","unstructured":"Bou Zerdan M, et al. Systemic AL amyloidosis: current approach and future direction. Oncotarget. 2023;14:384\u201394.","journal-title":"Oncotarget"},{"issue":"4","key":"2050_CR50","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13681","volume":"107","author":"S Oubari","year":"2021","unstructured":"Oubari S, et al. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. Eur J Haematol. 2021;107(4):449\u201357.","journal-title":"Eur J Haematol"},{"issue":"9","key":"2050_CR51","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","volume":"34","author":"R Ry\u0161av\u00e1","year":"2019","unstructured":"Ry\u0161av\u00e1 R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019;34(9):1460\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2050_CR52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","volume":"114","author":"O Landgren","year":"2009","unstructured":"Landgren O, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009;114(4):791\u20135.","journal-title":"Blood"},{"key":"2050_CR53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-022-00700-x","volume":"12","author":"S Cingam","year":"2022","unstructured":"Cingam S, Sidana S. Differential diagnosis of Waldenstr\u00f6m\u2019s macroglobulinemia and early management: perspectives from clinical practice. Blood Lymphat Cancer. 2022;12:107\u201317.","journal-title":"Blood Lymphat Cancer"},{"issue":"6","key":"2050_CR54","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1097\/HS9.0000000000000502","volume":"4","author":"MC Da Vi\u00e0","year":"2020","unstructured":"Da Vi\u00e0 MC, et al. A journey through myeloma evolution: from the normal plasma cell to disease complexity. Hemasphere. 2020;4(6):e502.","journal-title":"Hemasphere"},{"issue":"1","key":"2050_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/eji.201847517","volume":"49","author":"J Tellier","year":"2019","unstructured":"Tellier J, Nutt SL. Plasma cells: the programming of an antibody-secreting machine. Eur J Immunol. 2019;49(1):30\u20137.","journal-title":"Eur J Immunol"},{"key":"2050_CR56","doi-asserted-by":"crossref","unstructured":"Wickramasinghe SN, Porwit A, Erber WN. CHAPTER 2 - Normal bone marrow cells: Development and cytology, in Blood and Bone Marrow Pathology (Second Edition), A. Porwit, J. McCullough, and W.N. Erber, Editors. 2011, Churchill Livingstone: Edinburgh. pp. 19\u201344.","DOI":"10.1016\/B978-0-7020-3147-2.00002-X"},{"issue":"4","key":"2050_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.beha.2005.02.002","volume":"18","author":"S Chen-Kiang","year":"2005","unstructured":"Chen-Kiang S. Biology of plasma cells. Best Pract Res Clin Haematol. 2005;18(4):493\u2013507.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2050_CR58","doi-asserted-by":"crossref","unstructured":"Trezise S et al. Mining the plasma cell transcriptome for novel cell surface proteins. Int J Mol Sci. 2018;19(8):2161.","DOI":"10.3390\/ijms19082161"},{"issue":"1","key":"2050_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","volume":"482","author":"F Fend","year":"2023","unstructured":"Fend F, Dogan A, Cook JR. Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch. 2023;482(1):163\u201377.","journal-title":"Virchows Arch"},{"issue":"1","key":"2050_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/imr.12011","volume":"251","author":"VT Chu","year":"2013","unstructured":"Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev. 2013;251(1):177\u201388.","journal-title":"Immunol Rev"},{"issue":"11","key":"2050_CR61","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.3390\/ijms20112822","volume":"20","author":"A Allegra","year":"2019","unstructured":"Allegra A, et al. Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma. Int J Mol Sci. 2019;20(11):2822.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"2050_CR62","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860\u201373.","journal-title":"N Engl J Med"},{"key":"2050_CR63","doi-asserted-by":"publisher","first-page":"p941820","DOI":"10.1155\/2014\/941820","volume":"2014","author":"DS Lee","year":"2014","unstructured":"Lee DS, Chng WJ, Shimizu K. Plasma cell neoplasms: genetics, pathobiology, and new therapeutic strategies. Biomed Res Int. 2014;2014:p941820.","journal-title":"Biomed Res Int"},{"key":"2050_CR64","doi-asserted-by":"publisher","first-page":"719140","DOI":"10.3389\/fonc.2021.719140","volume":"11","author":"S Perincheri","year":"2021","unstructured":"Perincheri S. Tumor microenvironment of lymphomas and plasma cell neoplasms: broad overview and impact on evaluation for immune based therapies. Front Oncol. 2021;11:719140.","journal-title":"Front Oncol"},{"issue":"10","key":"2050_CR65","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1038\/bcj.2015.92","volume":"5","author":"AM Rajan","year":"2015","unstructured":"Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5(10):e365\u2013365.","journal-title":"Blood Cancer J"},{"issue":"7","key":"2050_CR66","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2050_CR67","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"key":"2050_CR68","doi-asserted-by":"publisher","DOI":"10.5603\/AHP.2021.0004","author":"S Goldman-Mazur","year":"2021","unstructured":"Goldman-Mazur S, Vesole DH, Jurczyszyn A. Clinical implications of cytogenetic and molecular aberrations in multiple myeloma. Acta Haematol Pol. 2021. https:\/\/doi.org\/10.5603\/AHP.2021.0004.","journal-title":"Acta Haematol Pol"},{"issue":"Suppl 1","key":"2050_CR69","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ijlh.12360","volume":"37","author":"M Chesi","year":"2015","unstructured":"Chesi M, Bergsagel PL. Advances in the pathogenesis and diagnosis of multiple myeloma. Int J Lab Hematol. 2015;37(Suppl 1):108\u201314.","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"2050_CR70","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/leu.2016.253","volume":"31","author":"JR Sawyer","year":"2017","unstructured":"Sawyer JR, et al. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia. 2017;31(3):637\u201344.","journal-title":"Leukemia"},{"issue":"3","key":"2050_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-019-0182-z","volume":"9","author":"JF Peterson","year":"2019","unstructured":"Peterson JF, et al. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J. 2019;9(3):20.","journal-title":"Blood Cancer J"},{"issue":"2","key":"2050_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Reviews Clin Oncol. 2017;14(2):100\u201313.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"17","key":"2050_CR73","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","volume":"121","author":"BA Walker","year":"2013","unstructured":"Walker BA, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121(17):3413\u20139.","journal-title":"Blood"},{"issue":"1","key":"2050_CR74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2019004309","volume":"137","author":"J Corre","year":"2021","unstructured":"Corre J, Munshi NC, Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a revision? Blood. 2021;137(1):16\u20139.","journal-title":"Blood"},{"key":"2050_CR75","doi-asserted-by":"publisher","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168.","journal-title":"Blood Rev"},{"issue":"12","key":"2050_CR76","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1038\/leu.2012.128","volume":"26","author":"L L\u00f3pez-Corral","year":"2012","unstructured":"L\u00f3pez-Corral L, et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia. 2012;26(12):2521\u20139.","journal-title":"Leukemia"},{"issue":"13","key":"2050_CR77","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood.2022016212","volume":"141","author":"N Stong","year":"2023","unstructured":"Stong N, et al. The location of the t (4; 14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood. 2023;141(13):1574\u201383.","journal-title":"Blood"},{"issue":"1","key":"2050_CR78","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1038\/s41598-020-62885-0","volume":"10","author":"M Baysal","year":"2020","unstructured":"Baysal M, et al. Concepts of double hit and triple hit disease in multiple Myeloma, entity and prognostic significance. Sci Rep. 2020;10(1):5991.","journal-title":"Sci Rep"},{"issue":"6","key":"2050_CR79","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","volume":"106","author":"WJ Chng","year":"2005","unstructured":"Chng WJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106(6):2156\u201361.","journal-title":"Blood"},{"issue":"1","key":"2050_CR80","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","volume":"12","author":"EM Boyle","year":"2021","unstructured":"Boyle EM, et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021;12(1):293.","journal-title":"Nat Commun"},{"issue":"21","key":"2050_CR81","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros M, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020;38(21):2380\u20139.","journal-title":"J Clin Oncol"},{"key":"2050_CR82","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2018.00665","volume":"8","author":"KK Jovanovi\u0107","year":"2018","unstructured":"Jovanovi\u0107 KK, et al. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2018;8:665.","journal-title":"Front Oncol"},{"issue":"8","key":"2050_CR83","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","volume":"28","author":"M Affer","year":"2014","unstructured":"Affer M, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28(8):1725\u201335.","journal-title":"Leukemia"},{"issue":"2","key":"2050_CR84","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","volume":"13","author":"M Chesi","year":"2008","unstructured":"Chesi M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167\u201380.","journal-title":"Cancer Cell"},{"issue":"4","key":"2050_CR85","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.7150\/ijbs.78535","volume":"19","author":"X-P Li","year":"2023","unstructured":"Li X-P, et al. The emerging role of Super-enhancers as therapeutic targets in the digestive system tumors. Int J Biol Sci. 2023;19(4):1036\u201348.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2050_CR86","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1349-7006.2004.tb03171.x","volume":"95","author":"A Kaneda","year":"2004","unstructured":"Kaneda A, et al. Frequent hypomethylation in multiple promoter CpG Islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci. 2004;95(1):58\u201364.","journal-title":"Cancer Sci"},{"issue":"5618","key":"2050_CR87","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.1083557","volume":"300","author":"A Eden","year":"2003","unstructured":"Eden A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300(5618):455.","journal-title":"Science"},{"issue":"6","key":"2050_CR88","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.4049\/jimmunol.1202493","volume":"190","author":"CJ Heuck","year":"2013","unstructured":"Heuck CJ, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013;190(6):2966\u201375.","journal-title":"J Immunol"},{"issue":"12","key":"2050_CR89","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.4161\/15592294.2014.983379","volume":"9","author":"M Almamun","year":"2014","unstructured":"Almamun M, et al. Genome-wide DNA methylation analysis in precursor B-cells. Epigenetics. 2014;9(12):1588\u201395.","journal-title":"Epigenetics"},{"issue":"4","key":"2050_CR90","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1101\/gr.180240.114","volume":"25","author":"X Agirre","year":"2015","unstructured":"Agirre X, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 2015;25(4):478\u201387.","journal-title":"Genome Res"},{"issue":"12","key":"2050_CR91","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood.2023023639","volume":"144","author":"K Chohan","year":"2024","unstructured":"Chohan K, et al. Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation. Blood. 2024;144(12):1284\u20139.","journal-title":"Blood"},{"issue":"26","key":"2050_CR92","first-page":"6871","volume":"118","author":"S D\u2019Souza","year":"2011","unstructured":"D\u2019Souza S, et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood J Am Soc Hematol. 2011;118(26):6871\u201380.","journal-title":"Blood J Am Soc Hematol"},{"issue":"47","key":"2050_CR93","doi-asserted-by":"publisher","first-page":"33530","DOI":"10.1074\/jbc.M113.497040","volume":"288","author":"D Yang","year":"2013","unstructured":"Yang D, et al. Histone demethylase Jmjd3 regulates osteoblast differentiation via transcription factors Runx2 and Osterix. J Biol Chem. 2013;288(47):33530\u201341.","journal-title":"J Biol Chem"},{"issue":"4","key":"2050_CR94","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","volume":"15","author":"J Adamik","year":"2017","unstructured":"Adamik J, et al. EZH2 or HDAC1 Inhibition reverses multiple Myeloma-Induced epigenetic suppression of osteoblast differentiation. Mol Cancer Res. 2017;15(4):405\u201317.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"2050_CR95","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1101\/gr.265520.120","volume":"30","author":"R Ordo\u00f1ez","year":"2020","unstructured":"Ordo\u00f1ez R, et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Res. 2020;30(9):1217\u201327.","journal-title":"Genome Res"},{"issue":"5","key":"2050_CR96","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijbs.92988","volume":"20","author":"W-X Xu","year":"2024","unstructured":"Xu W-X, et al. The burgeoning significance of Liquid-Liquid phase separation in the pathogenesis and therapeutics of cancers. Int J Biol Sci. 2024;20(5):1652\u201368.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2050_CR97","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1038\/s41467-021-25704-2","volume":"12","author":"J Alvarez-Benayas","year":"2021","unstructured":"Alvarez-Benayas J, et al. Chromatin-based, in Cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. Nat Commun. 2021;12(1):5450.","journal-title":"Nat Commun"},{"issue":"1","key":"2050_CR98","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun. 2019;10(1):1911.","journal-title":"Nat Commun"},{"key":"2050_CR99","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-43624-1_7","volume":"945","author":"R Lakshminarasimhan","year":"2016","unstructured":"Lakshminarasimhan R, Liang G. The role of DNA methylation in cancer. Adv Exp Med Biol. 2016;945:151\u201372.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2050_CR100","doi-asserted-by":"publisher","first-page":"104268","DOI":"10.1016\/j.lpm.2025.104268","volume":"54","author":"C Saade","year":"2025","unstructured":"Saade C, Ghobrial IM. Updates on mechanisms of disease progression in precursor myeloma: monoclonal gammopathy of undermined significance and smoldering myeloma. La Presse M\u00e9dicale. 2025;54(1):104268.","journal-title":"La Presse M\u00e9dicale"},{"issue":"1","key":"2050_CR101","doi-asserted-by":"publisher","first-page":"18079","DOI":"10.1038\/s41598-017-18056-9","volume":"7","author":"Y Sun","year":"2017","unstructured":"Sun Y, et al. Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-\u03baB pathway. Sci Rep. 2017;7(1):18079.","journal-title":"Sci Rep"},{"issue":"22","key":"2050_CR102","doi-asserted-by":"publisher","first-page":"11283","DOI":"10.18632\/oncotarget.2207","volume":"5","author":"K Beider","year":"2014","unstructured":"Beider K, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4\/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget. 2014;5(22):11283\u201396.","journal-title":"Oncotarget"},{"issue":"1","key":"2050_CR103","first-page":"6268514","volume":"2020","author":"M-H Bao","year":"2020","unstructured":"Bao M-H, et al. A novel putative role of TNK1 in atherosclerotic inflammation implicating the Tyk2\/STAT1 pathway. Mediat Inflamm. 2020;2020(1):6268514.","journal-title":"Mediat Inflamm"},{"key":"2050_CR104","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","volume":"414","author":"J Hu","year":"2018","unstructured":"Hu J, Hu W-X. Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments. Cancer Lett. 2018;414:214\u201321.","journal-title":"Cancer Lett"},{"issue":"5","key":"2050_CR105","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1365-2141.2007.06686.x","volume":"138","author":"L Trentin","year":"2007","unstructured":"Trentin L, et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol. 2007;138(5):594\u2013602.","journal-title":"Br J Haematol"},{"issue":"14","key":"2050_CR106","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.7150\/ijms.48244","volume":"17","author":"Q Yang","year":"2020","unstructured":"Yang Q, et al. Identification of key genes and pathways in myeloma side population cells by bioinformatics analysis. Int J Med Sci. 2020;17(14):2063\u201376.","journal-title":"Int J Med Sci"},{"issue":"14","key":"2050_CR107","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2009-03-211045","volume":"115","author":"JJ Driscoll","year":"2010","unstructured":"Driscoll JJ, et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010;115(14):2827\u201334.","journal-title":"Blood"},{"key":"2050_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2024.100625","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024;5(3).\u00a0https:\/\/doi.org\/10.1016\/j.xinn.2024.100625.","journal-title":"Innovation"},{"key":"2050_CR109","doi-asserted-by":"publisher","first-page":"101177","DOI":"10.1016\/j.neo.2025.101177","volume":"66","author":"S Crist\u00f3bal-Vargas","year":"2025","unstructured":"Crist\u00f3bal-Vargas S, Cuadrado M, Guti\u00e9rrez NC. MYC alterations in multiple myeloma: genetic insights and prognostic impact. Neoplasia. 2025;66:101177.","journal-title":"Neoplasia"},{"issue":"1","key":"2050_CR110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hon.704","volume":"21","author":"M Raitakari","year":"2003","unstructured":"Raitakari M, et al. T cells in myeloma. Hematol Oncol. 2003;21(1):33\u201342.","journal-title":"Hematol Oncol"},{"issue":"8","key":"2050_CR111","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/sj.leu.2400714","volume":"11","author":"RD Brown","year":"1997","unstructured":"Brown RD, et al. The prognostic significance of T cell receptor \u03b2 gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia. 1997;11(8):1312\u20137.","journal-title":"Leukemia"},{"issue":"2","key":"2050_CR112","first-page":"384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, et al. Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of Antiplasma cell activity in multiple myeloma. Blood J Am Soc Hematol. 2000;96(2):384\u201392.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"2050_CR113","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1006\/clim.2000.4982","volume":"98","author":"TM Ellis","year":"2001","unstructured":"Ellis TM, et al. Alterations in CD30(+) T cells in monoclonal gammopathy of undetermined significance. Clin Immunol. 2001;98(3):301\u20137.","journal-title":"Clin Immunol"},{"key":"2050_CR114","doi-asserted-by":"publisher","first-page":"145293","DOI":"10.1155\/2015\/145293","volume":"2015","author":"S Hermouet","year":"2015","unstructured":"Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm. 2015;2015:145293.","journal-title":"Mediators Inflamm"},{"key":"2050_CR115","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95367","author":"A Bosseboeuf","year":"2017","unstructured":"Bosseboeuf A, et al. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens. JCI Insight. 2017. https:\/\/doi.org\/10.1172\/jci.insight.95367.","journal-title":"JCI Insight"},{"issue":"7","key":"2050_CR116","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.molimm.2006.09.005","volume":"44","author":"BJ Scallon","year":"2007","unstructured":"Scallon BJ, et al. Higher levels of sialylated Fc glycans in Immunoglobulin G molecules can adversely impact functionality. Mol Immunol. 2007;44(7):1524\u201334.","journal-title":"Mol Immunol"},{"issue":"5","key":"2050_CR117","first-page":"2040","volume":"26","author":"Y Huang","year":"2021","unstructured":"Huang Y, et al. Integrated analysis of hub gene expression in multiple myeloma. J Buon. 2021;26(5):2040\u201352.","journal-title":"J Buon"},{"issue":"8","key":"2050_CR118","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","volume":"16","author":"E Terpos","year":"2005","unstructured":"Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16(8):1223\u201331.","journal-title":"Ann Oncol"},{"issue":"3","key":"2050_CR119","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00774-023-01403-4","volume":"41","author":"J Teramachi","year":"2023","unstructured":"Teramachi J, et al. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents. J Bone Min Metab. 2023;41(3):388\u2013403.","journal-title":"J Bone Min Metab"},{"issue":"5","key":"2050_CR120","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel H, et al. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33(5):1063\u201375.","journal-title":"Leukemia"},{"issue":"10","key":"2050_CR121","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/sj.leu.2404875","volume":"21","author":"D Dingli","year":"2007","unstructured":"Dingli D, Russell SJ. Mouse models and the RANKL\/OPG axis in myeloma bone disease. Leukemia. 2007;21(10):2090\u20133.","journal-title":"Leukemia"},{"issue":"4","key":"2050_CR122","first-page":"334","volume":"33","author":"PC Chan","year":"2022","unstructured":"Chan PC, Karin A, Chow S. A case of clinical confusion due to erroneous M-protein quantifications: to splice or skim? EJIFCC. 2022;33(4):334\u201341.","journal-title":"EJIFCC"},{"issue":"23","key":"2050_CR123","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1182\/blood.V126.23.5308.5308","volume":"126","author":"KKS Abbi","year":"2015","unstructured":"Abbi KKS, et al. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma. Blood. 2015;126(23):5308.","journal-title":"Blood"},{"issue":"22","key":"2050_CR124","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","volume":"122","author":"B Paiva","year":"2013","unstructured":"Paiva B, et al. Detailed characterization of multiple myeloma Circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591\u20138.","journal-title":"Blood"},{"key":"2050_CR125","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5772\/64124","volume":"5","author":"L Zhang","year":"2016","unstructured":"Zhang L, et al. Detection and characterization of Circulating tumour cells in multiple myeloma. J Circ Biomark. 2016;5:10.","journal-title":"J Circ Biomark"},{"key":"2050_CR126","doi-asserted-by":"crossref","unstructured":"Li L et al. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis. Front Immunol, 2024. Volume 15\u20132024.","DOI":"10.3389\/fimmu.2024.1381212"},{"issue":"10","key":"2050_CR127","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/ajh.27414","volume":"99","author":"IV Kostopoulos","year":"2024","unstructured":"Kostopoulos IV, et al. Low Circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma. Am J Hematol. 2024;99(10):1887\u201396.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"2050_CR128","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2021-145971","volume":"138","author":"C Fokkema","year":"2021","unstructured":"Fokkema C, et al. High levels of circulating tumor cells are associated with increased bone marrow proliferation in newly diagnosed multiple myeloma patients. Blood. 2021;138(Supplement 1):1566\u20131566.","journal-title":"Blood"},{"key":"2050_CR129","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","volume":"13","author":"A Dutta","year":"2022","unstructured":"Dutta A, et al. MinimuMM-seq: genome sequencing of Circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. Cancer Discov. 2022;13:348\u201363.","journal-title":"Cancer Discov"},{"issue":"27","key":"2050_CR130","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, et al. High levels of Circulating tumor plasma cells as a key hallmark of aggressive disease in Transplant-Eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(27):3120\u201331.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2050_CR131","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1200\/JCO.22.01606","volume":"41","author":"IV Kostopoulos","year":"2023","unstructured":"Kostopoulos IV, et al. Circulating plasma cells in newly diagnosed multiple myeloma: prognostic and more. J Clin Oncol. 2023;41(3):708\u201310.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2050_CR132","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek T, et al. More than 2% of Circulating tumor plasma cells defines plasma cell Leukemia-Like multiple myeloma. J Clin Oncol. 2023;41(7):1383\u201392.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2050_CR133","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.25709","volume":"95","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying Circulating clonal plasma cells. Am J Hematol. 2020;95(3):310\u20135.","journal-title":"Am J Hematol"},{"issue":"3","key":"2050_CR134","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bjh.17118","volume":"193","author":"P Galieni","year":"2021","unstructured":"Galieni P, et al. The detection of Circulating plasma cells May improve the revised international staging system (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. Br J Haematol. 2021;193(3):542\u201350.","journal-title":"Br J Haematol"},{"issue":"27","key":"2050_CR135","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"J-J Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s J-J, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol. 2022;40(27):3151\u201361.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2050_CR136","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8(1):268.","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"2050_CR137","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1182\/blood-2024-206782","volume":"144","author":"A Uehara","year":"2024","unstructured":"Uehara A, et al. Different patterns of antigen expression in bone marrow and circulating tumor plasma cells in patients with MGUS and smoldering multiple myeloma. Blood. 2024;144(Supplement 1):4682\u20134682.","journal-title":"Blood"},{"issue":"9","key":"2050_CR138","doi-asserted-by":"publisher","first-page":"e70218","DOI":"10.1002\/hem3.70218","volume":"9","author":"J-J Garces","year":"2025","unstructured":"Garces J-J, et al. Elevated Circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma. HemaSphere. 2025;9(9):e70218.","journal-title":"HemaSphere"},{"issue":"11","key":"2050_CR139","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42(11):1229\u201340.","journal-title":"J Clin Oncol"},{"key":"2050_CR140","unstructured":"Bertamini L et al. Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. Blood. 2025;blood-2025030113."},{"issue":"1","key":"2050_CR141","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2496796","volume":"57","author":"D Liang","year":"2025","unstructured":"Liang D, et al. Clinical outcome of \u2265 2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study. Ann Med. 2025;57(1):2496796.","journal-title":"Ann Med"},{"issue":"24","key":"2050_CR142","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, et al. International myeloma Society\/International myeloma working group consensus recommendations on the definition of High-Risk multiple myeloma. J Clin Oncol. 2025;43(24):2739\u201351.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2050_CR143","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron AC, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932\u20135.","journal-title":"Blood"},{"issue":"1","key":"2050_CR144","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A Meta-analysis. JAMA Oncol. 2017;3(1):28\u201335.","journal-title":"JAMA Oncol"},{"issue":"12","key":"2050_CR145","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bmt.2016.222","volume":"51","author":"O Landgren","year":"2016","unstructured":"Landgren O, et al. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transpl. 2016;51(12):1565\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2050_CR146","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/cyto.b.21268","volume":"90","author":"NJ Gormley","year":"2016","unstructured":"Gormley NJ, et al. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):73\u201380.","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"2050_CR147","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10428194.2016.1228930","volume":"58","author":"R Gupta","year":"2017","unstructured":"Gupta R, et al. Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma. Leuk Lymphoma. 2017;58(5):1234\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2050_CR148","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/ajh.23813","volume":"89","author":"A Litvak","year":"2014","unstructured":"Litvak A, et al. Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis. Am J Hematol. 2014;89(12):1153\u20134.","journal-title":"Am J Hematol"},{"issue":"1","key":"2050_CR149","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cyto.b.21271","volume":"90","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, et al. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: lessons from the past 20 years at the Leeds haematological malignancy diagnostic service. Cytometry B Clin Cytom. 2016;90(1):54\u201360.","journal-title":"Cytometry B Clin Cytom"},{"issue":"20","key":"2050_CR150","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073\u20139.","journal-title":"Blood"},{"issue":"1","key":"2050_CR151","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.15075","volume":"181","author":"Y Bai","year":"2018","unstructured":"Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181(1):11\u201326.","journal-title":"Br J Haematol"},{"issue":"10","key":"2050_CR152","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1038\/bcj.2014.69","volume":"4","author":"R Silvennoinen","year":"2014","unstructured":"Silvennoinen R, et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood Cancer J. 2014;4(10):e250.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2050_CR153","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-016-0336-4","volume":"9","author":"Y Bai","year":"2016","unstructured":"Bai Y, et al. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers\/probes. J Hematol Oncol. 2016;9(1):107.","journal-title":"J Hematol Oncol"},{"key":"2050_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205169","author":"JM Rosa-Rosa","year":"2022","unstructured":"Rosa-Rosa JM, et al. NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial. Cancers (Basel). 2022;5169.\u00a0https:\/\/doi.org\/10.3390\/cancers14205169.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"2050_CR155","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2019001077","volume":"134","author":"PA Thompson","year":"2019","unstructured":"Thompson PA, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134(22):1951\u20139.","journal-title":"Blood"},{"issue":"3","key":"2050_CR156","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-018-0062-y","volume":"8","author":"BS White","year":"2018","unstructured":"White BS, et al. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J. 2018;8(3):35.","journal-title":"Blood Cancer J"},{"issue":"12","key":"2050_CR157","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","volume":"9","author":"V Yellapantula","year":"2019","unstructured":"Yellapantula V, et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019;9(12):101.","journal-title":"Blood Cancer J"},{"key":"2050_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051332","author":"M Manzoni","year":"2020","unstructured":"Manzoni M, et al. Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma. Cancers (Basel). 2020;1853\u20131868.\u00a0https:\/\/doi.org\/10.3390\/cancers12051332.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2050_CR159","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812\u20137.","journal-title":"Blood"},{"issue":"3","key":"2050_CR160","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3390\/curroncol28030188","volume":"28","author":"C Tessier","year":"2021","unstructured":"Tessier C, et al. Testing Mayo clinic\u2019s new 20\/20\/20 risk model in another cohort of smoldering myeloma patients: A retrospective study. Curr Oncol. 2021;28(3):2029\u201339.","journal-title":"Curr Oncol"},{"issue":"26","key":"2050_CR161","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"29","key":"2050_CR162","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406\u201318.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2050_CR163","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41408-024-01149-w","volume":"14","author":"PG Richardson","year":"2024","unstructured":"Richardson PG, et al. Allocation and validation of the second revision of the international staging system in the ICARIA-MM and IKEMA studies. Blood Cancer J. 2024;14(1):209.","journal-title":"Blood Cancer J"},{"issue":"14","key":"2050_CR164","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1097\/CM9.0000000000002735","volume":"136","author":"W Yan","year":"2023","unstructured":"Yan W, et al. Prognostic value of the second revision of the international staging system (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma. Chin Med J (Engl). 2023;136(14):1744\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"2050_CR165","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"E Monika","year":"2017","unstructured":"Monika E, et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910\u201321.","journal-title":"Haematologica"},{"issue":"9","key":"2050_CR166","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1016\/S2666-7568(22)00172-6","volume":"3","author":"F Efficace","year":"2022","unstructured":"Efficace F, et al. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. Lancet Healthy Longev. 2022;3(9):e628\u201335.","journal-title":"Lancet Healthy Longev"},{"key":"2050_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102465","author":"F Schjesvold","year":"2021","unstructured":"Schjesvold F, Oriol A. Current and novel alkylators in multiple myeloma. Cancers (Basel). 2021;2465.\u00a0https:\/\/doi.org\/10.3390\/cancers13102465.","journal-title":"Cancers (Basel)"},{"key":"2050_CR168","first-page":"100522","volume":"24","author":"R Mecklenbrauck","year":"2025","unstructured":"Mecklenbrauck R, et al. Pharmacokinetics and outcome of high-dose Melphalan followed by autologous stem cell transplantation in dialysis-dependent patients with multiple myeloma. Leuk Res Rep. 2025;24:100522.","journal-title":"Leuk Res Rep"},{"key":"2050_CR169","doi-asserted-by":"publisher","first-page":"1061417","DOI":"10.3389\/fonc.2022.1061417","volume":"12","author":"F McKenzie","year":"2022","unstructured":"McKenzie F, et al. Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews. Front Oncol. 2022;12:1061417.","journal-title":"Front Oncol"},{"issue":"8","key":"2050_CR170","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jjco\/hyz083","volume":"49","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ishida T. Immunomodulatory drugs in the treatment of multiple myeloma. Jpn J Clin Oncol. 2019;49(8):695\u2013702.","journal-title":"Jpn J Clin Oncol"},{"key":"2050_CR171","doi-asserted-by":"publisher","first-page":"341430","DOI":"10.1155\/2015\/341430","volume":"2015","author":"WC Yang","year":"2015","unstructured":"Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015;2015:341430.","journal-title":"Biomed Res Int"},{"issue":"1","key":"2050_CR172","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, et al. Mechanism of action of Immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22\u201332.","journal-title":"Leukemia"},{"issue":"5","key":"2050_CR173","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017;77(5):505\u201320.","journal-title":"Drugs"},{"issue":"1","key":"2050_CR174","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.4081\/hr.2015.5704","volume":"7","author":"UH Patel","year":"2015","unstructured":"Patel UH, et al. Central neurotoxicity of Immunomodulatory drugs in multiple myeloma. Hematol Rep. 2015;7(1):5704.","journal-title":"Hematol Rep"},{"issue":"8","key":"2050_CR175","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1021\/mp300044b","volume":"9","author":"L Ao","year":"2012","unstructured":"Ao L, et al. Development of Peptide-Based reversing agents for P-Glycoprotein-Mediated resistance to Carfilzomib. Mol Pharm. 2012;9(8):2197\u2013205.","journal-title":"Mol Pharm"},{"key":"2050_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030963","author":"P Kulig","year":"2023","unstructured":"Kulig P, et al. Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives. Cancers (Basel). 2023;963.\u00a0https:\/\/doi.org\/10.3390\/cancers15030963.","journal-title":"Cancers (Basel)"},{"key":"2050_CR177","doi-asserted-by":"publisher","first-page":"851688","DOI":"10.3389\/fgene.2022.851688","volume":"13","author":"R Sikander","year":"2022","unstructured":"Sikander R, et al. Identification of the ubiquitin-proteasome pathway domain by hyperparameter optimization based on a 2D convolutional neural network. Front Genet. 2022;13:851688.","journal-title":"Front Genet"},{"issue":"4","key":"2050_CR178","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cncr.32601","volume":"126","author":"B Fakhri","year":"2020","unstructured":"Fakhri B, et al. Measuring cardiopulmonary complications of Carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer. 2020;126(4):808\u201313.","journal-title":"Cancer"},{"issue":"8","key":"2050_CR179","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","volume":"112","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107\u201314.","journal-title":"Blood"},{"issue":"23","key":"2050_CR180","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood.V126.23.727.727","volume":"126","author":"P Moreau","year":"2015","unstructured":"Moreau P, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with Lenalidomide and dexamethasone (IRd), significantly extends Progression-Free survival (PFS) for patients (Pts) with relapsed and\/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 study (NCT01564537). Blood. 2015;126(23):727.","journal-title":"Blood"},{"key":"2050_CR181","doi-asserted-by":"publisher","first-page":"123125","DOI":"10.1016\/j.lfs.2024.123125","volume":"358","author":"O Sogbein","year":"2024","unstructured":"Sogbein O, et al. Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors. Life Sci. 2024;358:123125.","journal-title":"Life Sci"},{"issue":"1","key":"2050_CR182","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):51.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2050_CR183","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1093\/oncolo\/oyac067","volume":"27","author":"AJ Jakubowiak","year":"2022","unstructured":"Jakubowiak AJ, et al. Daratumumab improves depth of response and Progression-free survival in Transplant-ineligible, High-risk, newly diagnosed multiple myeloma. Oncologist. 2022;27(7):e589\u201396.","journal-title":"Oncologist"},{"issue":"10214","key":"2050_CR184","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, et al. Isatuximab plus Pomalidomide and low-dose dexamethasone versus Pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096\u2013107.","journal-title":"Lancet"},{"issue":"9","key":"2050_CR185","doi-asserted-by":"publisher","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","volume":"6","author":"T Pazina","year":"2017","unstructured":"Pazina T, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology. 2017;6(9):e1339853.","journal-title":"Oncoimmunology"},{"key":"2050_CR186","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/B978-0-323-46143-6.00025-7","volume-title":"Nanostructures for Drug Delivery","author":"DA Quinteros","year":"2017","unstructured":"Quinteros DA. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. In: Nanostructures for Drug Delivery, vol. 1, 2017. p. 807\u2013833."},{"key":"2050_CR187","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2147\/JIR.S499403","volume":"18","author":"S Zhang","year":"2025","unstructured":"Zhang S, et al. The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy. J Inflamm Res. 2025;18:4335\u201357.","journal-title":"J Inflamm Res"},{"issue":"8","key":"2050_CR188","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"issue":"12","key":"2050_CR189","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486\u201394.","journal-title":"Am J Hematol"},{"key":"2050_CR190","doi-asserted-by":"crossref","unstructured":"Weisel K et al. P09\u2003Daratumumab Plus Lenalidomide And Dexamethasone (D-RD) Versus Lenalidomide And Dexamethasone (RD) Alone In Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis Of The Phase 3 Maia Study Hemasphere, 2023;7(Suppl):1\u20139.","DOI":"10.1097\/01.HS9.0000936164.84357.ed"},{"issue":"4","key":"2050_CR191","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, et al. Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"2050_CR192","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon T, et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39(4):942\u201350.","journal-title":"Leukemia"},{"issue":"6","key":"2050_CR193","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"M-V Mateos","year":"2018","unstructured":"Mateos M-V, et al. Daratumumab plus Bortezomib, Melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328.","journal-title":"N Engl J Med"},{"key":"2050_CR194","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040606","author":"S Mor\u00e8","year":"2022","unstructured":"Mor\u00e8 S, et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? Cells. 2022;1\u201322.\u00a0https:\/\/doi.org\/10.3390\/cells11040606.","journal-title":"Cells"},{"issue":"3","key":"2050_CR195","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.2024025746","volume":"145","author":"A Badros","year":"2025","unstructured":"Badros A, et al. Daratumumab with Lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025;145(3):300\u201310.","journal-title":"Blood"},{"issue":"1","key":"2050_CR196","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41409-020-01023-w","volume":"56","author":"B Dhakal","year":"2021","unstructured":"Dhakal B, et al. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplant. 2021;56(1):9\u201319.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2050_CR197","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jhep.2025.06.007","volume":"83","author":"E Jaeckel","year":"2025","unstructured":"Jaeckel E, et al. Chimeric antigen receptor (CAR) T-cell therapy: engineering immune cells to treat liver diseases. J Hepatol. 2025;83(5):1156\u201371.","journal-title":"J Hepatol"},{"key":"2050_CR198","doi-asserted-by":"crossref","unstructured":"Abken H, Chmielewski M, Hombach AA. Antigen-Specific T-Cell activation independently of the MHC: chimeric antigen Receptor-Redirected T cells. Front Immunol, 2013. Volume 4\u20132013.","DOI":"10.3389\/fimmu.2013.00371"},{"issue":"18","key":"2050_CR199","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/cells13181596","volume":"13","author":"E Bartoszewska","year":"2024","unstructured":"Bartoszewska E, et al. Overcoming antigen escape and T-Cell exhaustion in CAR-T therapy for leukemia. Cells. 2024;13(18):1596.","journal-title":"Cells"},{"issue":"Supplement 1","key":"2050_CR200","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1182\/blood-2024-199913","volume":"144","author":"W Yan","year":"2024","unstructured":"Yan W, et al. BCMA CAR-T therapy as first-line consolidation treatment in transplant-ineligible patients with newly-diagnosed multiple myeloma: an open label, single-arm, phase 2 study (CAREMM-001). Blood. 2024;144(Supplement 1):3385\u20133385.","journal-title":"Blood"},{"issue":"14","key":"2050_CR201","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/cells14141077","volume":"14","author":"B Tedder","year":"2025","unstructured":"Tedder B, Bhutani M. Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-Cell therapies in multiple myeloma. Cells. 2025;14(14):1077.","journal-title":"Cells"},{"issue":"5","key":"2050_CR202","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"G Lancman","year":"2021","unstructured":"Lancman G, et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2021;2(5):423\u201333.","journal-title":"Blood Cancer Discov"},{"key":"2050_CR203","doi-asserted-by":"crossref","unstructured":"Rees M et al. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol, 2024. Volume 15\u20132024.","DOI":"10.3389\/fimmu.2024.1424925"},{"issue":"6","key":"2050_CR204","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"key":"2050_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01489-3","author":"J Zhao","year":"2023","unstructured":"Zhao J, et al. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s13045-023-01489-3.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2050_CR206","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024;14(1):27.","journal-title":"Blood Cancer J"},{"issue":"8","key":"2050_CR207","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"10297","key":"2050_CR208","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"8","key":"2050_CR209","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.ekir.2025.05.007","volume":"10","author":"G Cazzaniga","year":"2025","unstructured":"Cazzaniga G, et al. Machine learning for monoclonal gammopathies of renal significance risk stratification using clinical and pathology data. Kidney Int Rep. 2025;10(8):2680\u20139.","journal-title":"Kidney Int Rep"},{"issue":"12","key":"2050_CR210","first-page":"e50176","volume":"15","author":"KK Adhit","year":"2023","unstructured":"Adhit KK, et al. Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine. Cureus. 2023;15(12):e50176.","journal-title":"Cureus"},{"issue":"1","key":"2050_CR211","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41746-025-01636-9","volume":"8","author":"M Ferle","year":"2025","unstructured":"Ferle M, et al. Predicting progression events in multiple myeloma from routine blood work. Npj Digit Med. 2025;8(1):231.","journal-title":"Npj Digit Med"},{"issue":"15","key":"2050_CR212","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.3390\/electronics14153014","volume":"14","author":"A Santamar\u00eda","year":"2025","unstructured":"Santamar\u00eda A, et al. Machine Learning-Based predictive model for risk stratification of multiple myeloma from monoclonal gammopathy of undetermined significance. Electronics. 2025;14(15):3014.","journal-title":"Electronics"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02050-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T20:02:47Z","timestamp":1771963367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":212,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02050-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}